ASCO 2023 | Checkpoint inhibition and predicative biomarkers in nasopharynx cancer

Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the latest developments in immunotherapy and biomarker research for patients with nasopharynx cancer. Findings from the Phase III JUPITER-02 (NCT03581786) of toripalimab or placebo plus chemotherapy have demonstrated the superiority of toripalimab, an anti-PD-1 antibody. However, PD-1 has shown to be an inadequate biomarker and single agent pembrolizumab is insufficient, as shown in the KEYNOTE-122 trial (NCT02611960). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.